|Ms. Maria Halasz||CEO, MD & Exec. Director||496.45k||N/A||N/A|
|Mr. Koichiro Koike||Managing Director of Advangen Inc||216.72k||N/A||1957|
|Dr. Bart Wuurman||Chief Exec. Officer of Lyramid||288k||N/A||N/A|
|Dr. Graham Robertson||Head of R&D||N/A||N/A||N/A|
|Mr. Lee Tamplin||Company Sec.||N/A||N/A||N/A|
Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.
Cellmid Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.